Orphan Drugs Would Get User Fee Waivers With Greater Ease Under House Bill

02 Jul 2007
News

Anthony Vecchione a.vecchione@elsevier.com

Executive Summary

Provisions in the House version of the FDA user fee bill would raise the cut-off for an orphan drug to qualify for a user fee waiver from firms with less than $10 million in annual revenue to firms with less then $100 million

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS048526

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS048526

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Orphan Drugs Would Get User Fee Waivers With Greater Ease Under House Bill

News

Executive Summary

Related Content

Orphan Drugs May Grow More Common As Medicine Becomes More Personal

Orphan Drugs May Grow More Common As Medicine Becomes More Personal

Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008

Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert